Orphan compromise or sacrifice?

WASHINGTON - In its efforts to avoid ceilings on orphan drug revenues, the biotech industry may be preparing to offer significant concessions to lawmakers who may not be able to pass a sales cap in the first place, according to a pharmaceutical lobbyist who has been handicapping the issue.

Lynda Nersesian,deputy vice president of government relations at the Pharmaceutical Manufacturer's Association, said members of Congress would be attracted by the "tough" provisions of legislation under consideration by the boards of directors of the Industrial Biotechnology Association and the Association of Biotechnology Companies...